1. People's Republic of China Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Shandong Sinobioway Biomedicine Co., Ltd.

Shandong Sinobioway Biomedicine Co., Ltd.

002581.SZ
Shandong Sinobioway Biomedicine Co., Ltd.CN flagShenzhen Stock Exchange
3.33
CNY
-0.12
- -
2.20BMarket Cap

Total Valuation

Shandong Sinobioway Biomedicine Co., Ltd. carries a market capitalization of 2.20B, placing it among publicly traded companies globally. Its enterprise value stands at 4.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.20B
Enterprise Value4.87B

Share Statistics

Shandong Sinobioway Biomedicine Co., Ltd. currently has 659.74M shares outstanding.

Shares Outstanding659.74M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 17.18, and the price-to-book ratio stands at 6.63.

PE RatioN/A
PS Ratio17.18
PB Ratio6.63
P/TBV Ratio2.70
P/FCF Ratio37.75
P/OCF RatioN/A

Enterprise Valuation

EV / Sales17.20
EV / EBITDAN/A
EV / EBITN/A
EV / FCF37.78

Financial Position

Shandong Sinobioway Biomedicine Co., Ltd. maintains a current ratio of 3.65, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

Current Ratio3.65
Quick Ratio1.01
Debt / Equity3.03
Debt / EBITDA-0.52
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-16.50
Return on Assets (ROA)-6.21
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.57

Taxes

Income Tax-14.04M
Effective Tax RateN/A

Stock Price Statistics

Shandong Sinobioway Biomedicine Co., Ltd.'s stock has declined approximately -69.78221% over the past 52 weeks. The 50-day moving average sits at 4.71, while the 200-day moving average is 6.95.

Beta (5Y)N/A
52-Week Price Change-69.78221%
50-Day Moving Average4.71
200-Day Moving Average6.95
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Shandong Sinobioway Biomedicine Co., Ltd. generated 283.34M in revenue and converted that into -132.15M in net income, yielding earnings per share of -0.25. EBITDA reached -110.72M, while operating income came in at -110.72M.

Revenue283.34M
Gross Profit93.50M
Operating Income-110.72M
Pretax Income-177.41M
Net Income-132.15M
EBITDA-110.72M
EBIT-110.72M
Earnings Per Share (EPS)-0.25

Balance Sheet

Shandong Sinobioway Biomedicine Co., Ltd. holds 153.88M in cash and equivalents against 57.61M in total debt, resulting in a net debt position of -116.36M. Total book value stands at 734.19M, with working capital of 403.83M providing operational flexibility.

Cash & Cash Equivalents153.88M
Total Debt57.61M
Net Debt-116.36M
Equity (Book Value)734.19M
Book Value Per Share1.11
Working Capital403.83M

Cash Flow

After subtracting -128.96M in capital expenditures, free cash flow totaled -128.96M - equivalent to -0.20 per share.

Operating Cash FlowN/A
Capital Expenditures-128.96M
Free Cash Flow-128.96M
FCF Per Share-0.20

Margins

Shandong Sinobioway Biomedicine Co., Ltd. operates with a gross margin of 43.38, reflecting its pricing power and cost economics. The operating margin of -39.08 and net profit margin of -46.64 provide insight into operational efficiency.

Gross Margin43.38
Operating Margin-39.08
Pretax Margin-62.61
Profit Margin-46.64
EBITDA Margin-39.08

Dividends & Yields

The company's payout ratio of -0.55 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.00
Dividend YieldN/A
Payout Ratio-0.55
Shareholder Yield0.50
FCF Yield2.65

Stock Splits

Shandong Sinobioway Biomedicine Co., Ltd.'s most recent stock split took place on July 10, 2015 with a 1:2 split ratio.

Last Split Date7/10/2015
Split Ratio1:2

Scores

Shandong Sinobioway Biomedicine Co., Ltd. posts an Altman Z-Score of 16.28, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score16.28